Financial News

Nicox Third Quarter 2018 Business Update and Financial Highlights

  • NCX 470 Phase 2 clinical study initiated in Q3 2018 for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
  • Net revenue from VYZULTATM sales increased by 66% compared to Q2 2018

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company,

Read more

Nicox and Fera Pharmaceuticals to Focus on a Rare Disease Indication for Naproxcinod

  • Nicox and Fera Pharmaceuticals have amended their 2015 agreement for naproxcinod
  • Development, under the responsibility of Fera, will now focus on an undisclosed rare disease, which could potentially lead to an orphan drug designation for naproxcinod
  • Potential sales-based milestone increased to $40 million if annual sales reach $1 billion

Sophia Antipolis,

Read more

Nicox First Half 2018 Financial Results and Business Update

  • NCX 470 Phase 2 clinical study initiated in Q3 2018
  • NCX 4251 on track for U.S. IND filing in Q1 2019 to enable first-in-human Phase 2 clinical study

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmic company, today reported the financial results for the Nicox Group for the six months ending June 30,

Read more
More news